IL6 and hydrops fetalis: Given the modulatory effects of ziltivekimab on atherogenic inflammatory pathways, if the ZEUS trial also confirms similar clinical benefits, IL-6 blockade may emerge as a potential strategy for individuals with similar at-risk profiles for HF.